5414x Apr 2026

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update

: £13.0 million (+52.9%), driven by AMR and EMEAI growth. : Established a strategic collaboration with Cepheid (a

: £12.9 million (+27.4%), supported by synthetic biology. supported by synthetic biology.